Skip to content


Immunotherapy represents one of the greatest advances for people living with cancer, but off-target effects remain a challenge in the clinical setting.

Our technology is designed to unleash validated and proven proinflammatory mechanisms on tumors while preventing unwanted side effects on non-target tissue. We create systemically delivered targeted therapies that address the limitations of immuno-oncology.

Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies.



We are advancing a novel class of cancer biotherapeutics designed to enhance the body’s immune response to cancer.

These conditionally activated proinflammatory immune modulators, called INDUKINE™ molecules, are systemically administered in an inactive form and are selectively activated to deliver full biological potency of cytokines upon entering the tumor microenvironment.

Our team of experienced scientists invented our proprietary PREDATOR™ protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients.


How PREDATOR maximizes therapeutic potential while minimizing unwanted off-target effects


What’s in a name?

The company name is a powerful analogy to our scientific approach. A werewolf is a creature that goes unnoticed in day-to-day life but transforms into a dangerous predator under specific conditions. That is exactly what the medicines that we are developing do.

Our molecules are delivered systemically and remain inactive in the body as they are drawn to the tumor microenvironment, at which point they stimulate a powerful immune response and unleash an attack on cancer cells.

Our proven team

Our team brings together the unmatched determination and dedication of experienced physician-scientists and industry veterans with a proven track record in oncology drug development. Our combined expertise in oncology, immunology, and protein engineering is key for delivering effective cancer immunotherapies to the clinic and market to improve the lives of people who are living with cancer.
Meet our Team
Dan Hicklin, Ph.D.
President, Chief Executive Officer and Board member
Randi Isaacs, M.D.
Chief Medical Officer
Chulani Karunatilake, Ph.D.
Chief Technology Officer
Ellen Lubman, M.B.A.
Chief Business Officer
Tim Trost
Chief Financial Officer
Bill Winston, Ph.D.
Senior Vice President, Research

Press Releases

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
WATERTOWN, Mass., June 25, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
WATERTOWN, Mass., June 01, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 30, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More
See all news

Join Our Team

Are you someone who makes things happen? Do you want to work at a company that embraces the same ideals? We’re looking for vibrant, creative, forward-thinking people to join our team. Click the link below and let us know that you’re interested. We’d love to talk to you.
No Available Positions At This Time
Check back soon!
Explore opportunities now